The financing will support the cost-bearing that is key to DecisionRx's unique business model: DecisionRx can assume the full cost of delivering Medication Therapy Optimization to patients of Accountable Care Organizations, Medicare Advantage Plans, and self-insured employers. The facility is expected to fund lab testing and comprehensive medication reviews by DecisionRx pharmacists for over 100,000 patients. Medication Therapy Optimization has been shown to reduce total cost of care per Medicare patient by over
'This transaction strongly validates investors' belief in our innovative approach to improving patient outcomes by helping providers avoid medication failure at scale. Much attention is given to buying prescription medications at the right price, but our focus is on selecting the right medications in the first place,' said DecisionRx CEO
'We are pleased to partner with DecisionRx in this important phase of growth for the company,' said
As part of the transaction, Carlyle receives the option to acquire 25% of the outstanding equity of DecisionRx.
This transaction was led by Carlyle's Credit Strategic Solutions ('CSS') team, a group within the Global Credit business focused on private fixed income and asset-backed investments. The highly experienced team leverages the knowledge, sourcing, structuring, and breadth of the entire Carlyle investment platform to deliver tailored asset-focused financing solutions to businesses, specialty finance companies, banks, asset managers, and other originators and owners of diversified pools of assets.
As of
About DecisionRx
DecisionRx is a technology-enabled healthcare services company, improving patient outcomes and reducing healthcare costs by helping physicians optimize prescribing decisions for their patients. DecisionRx clinical pharmacists work on patients' behalf to mitigate medication failure by making personalized medication recommendations to prescribers, informed by the latest clinical and data-science, and delivered in a value-based care model. Medication failure accounts for at least 16% of total healthcare spending, and medication therapy optimization has been shown to reduce total annualized cost of care by
About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With
About
Contact:
Tel: 646-677-1295
Email: Kyle.Evans@westwicke.com
Tel: 212-813-4763
Email: Kristen.Ashton@carlyle.com
(C) 2024 Electronic News Publishing, source